bioretec

JUL - 6 2006

G 510(k) SUMMARY

For the Bioretec ActivaPin™

MANUFACTURER

Bioretec Ltd.
Hermiankatu 22, Modulight Building
FI-33720 Tampere
FINLAND

Contact person:
Ms. Mari Ruotsalainen
Quality Manager
Phone: +358 20 778 9514
Fax: +358 3 317 0225
Mari.Ruotsalainen@bioretec.com

Secondary Contact:
Jonathan S. Kahan
Hogan & Hartson L.L.P.
Phone: 202-637-3638
Fax: 202-637-5910
jskahan@hhlaw.com

Date prepared: April 25th, 2006

DEVICE NAME

Trade Name: Bioretec ActivaPin™

Common Name: Pin, Fixation

ESTABLISHMENT REGISTRATION NUMBER

Bioretec Ltd. has not yet obtained an Establishment Registration Number. Bioretec Ltd. will register following the FDA clearance.

DEVICE CLASSIFICATION AND PRODUCT CODE

Device Classification Name: Pin, Fixation, Smooth

Classification Panel: Orthopedic

Regulation Number: 21 CFR 888.3040

Product Code: HTY

bioretec

PREDICATE DEVICES

1. Inion OTPS™ Biodegradable Pin (K031712, K050275)
2. Bionx Implants Inc., SmartPin™ PDX, PLGA Pin (K003659)

DEVICE DESCRIPTION AND PRINCIPLES OF OPERATION

The **ActivaPin™** is indicated for fixation of bone fractures, osteotomies, arthrodeses and osteochondral fractures in the presence of appropriate immobilization. Pins are available in several different dimensions, including diameters of 1.5 – 3.2 mm and lengths of 20 – 70 mm.

ActivaPin™ is made of completely bioabsorbable poly(L-lactide-co-glycolide) (PLGA), and they degrade *in vivo* by hydrolysis into alpha-hydroxy acids that are metabolized by the body. As the operated bone fracture or osteotomy gains strength during healing, the **ActivaPin™** gradually loses its strength, however, maintaining its function at least 8 weeks. Bioabsorption takes place within two years thus eliminating the need for implant removal surgery.

EQUIVALENCE TO MARKETED PRODUCTS

The ActivaPin™ Bioabsorbable Pin is substantially equivalent to those the biodegradable pins cited as predicate devices above.

The Bioretec ActivaPin™ has the same intended use and principles of operation, and very similar technological characteristic as the predicate devices. Any differences between ActivaPin™ and predicate devices do not raise any questions of safety and effectiveness.

Non-clinical tests and *In vitro*–testing determined that the ActivaPin™ has substantially similar performance as compared to its predicate devices.

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

JUL - 6 2006

Bioretec Ltd.
Ms. Mari Ruotsalainen
Quality Manager
Hermiankatu 22, Modulight Building
FI-33720 Tampere
FINLAND

Re: K061164

Trade/Device Name: ActivaPin™
Regulation Number: 21 CFR 888.3040
Regulation Name: Smooth or threaded metallic bone fixation fastener
Regulatory Class: Class II
Product Code: HTY
Dated: April 25, 2006
Received: April 26, 2006

Dear Ms. Ruotsalainen:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or 240-276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,



Mark N. Melkerson
Director
Division of General, Restorative
and Neurological Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

bioretec

F Indications for Use Statement

Submitter: Bioretec Ltd.

510(k) Number: K061164

Device Name: ActivaPin™

Indications for Use:

The **ActivaPin™** is indicated for fixation of bone fractures, osteotomies, arthrodeses and osteochondral fractures in the presence of appropriate immobilization.

Contraindications:

1. Fractures and osteotomies of diaphyseal bone.
2. Fractures and osteotomies in weight bearing cancellous bone.
3. Situations where internal fixation is otherwise contraindicated, e.g., active or potential infection and where patient cooperation cannot be guaranteed.

Prescription Use X AND/OR Over-The-Counter Use No

(Part 21 CFR 801 Subpart D) (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Barbara Mullin

(Division Sign-Off)

Division of General, Restorative, and Neurological Devices

Page 1 of 1

510(k) Number K061164

(Division Sign-Off)
Division of General, Restorative, and Neurological Devices
510(k) Number